Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $20 price target on AMAG Pharmaceuticals after the company announced this morning that it intends to launch an authorized generic of Makena through generic manufacturer Prasco Laboratories, adding that Makena's loss of exclusivity "is now upon us." While he contends that the timing of the generic's approval "should surprise nobody," Raymond says this serves as a reminder to investors that a key threat to the business is now underway and remains on the sidelines. The analyst continues to model Makena revenue of $302M, $178M, $92M, and $29M for 2018-2021, adding that "the trajectory doesn't look pretty."